You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The companies are working together to secure US Food and Drug Administration Emergency Use Authorization for the digital droplet PCR test.
North Dakota-based MedScan Laboratory will collect patient samples and extract RNA for Fulgent's new NGS-based clinical assay for SARS-CoV-2.
The joint submission of the coronavirus assay is part of a long-standing collaboration between the two firms to put BioGX assays on the BD Max system.
The consortium is developing a real-time PCR test for host detection assays targeting epigenetic signatures and viral RNA for early-stage monitoring of potentially infected individuals.
The firms have entered into a strategic partnership to integrate their respective amplicon-based target enrichment technologies for use in NGS testing.
In announcing a national emergency on Friday, Trump paraded out executives from the private sector as the administration tries to increase testing capacity
The collaboration expands on an existing partnership between the companies announced in 2018 to develop POC tests for significant global health threats.
Prevencio said that the agreement with Microsoft involves sales of cardiac blood tests to hospitals, life science companies, and contract research organizations.
The company is working with the Institut Pasteur de Dakar to validate and manufacture the test at a new manufacturing site in DiaTropix, Senegal.
The company will offer a 32-gene polygenic score test to patients in the Osaka, Japan Nakanoshima Clinic, with reporting and patient support help from IxLayer.